Clinical trial Recruiting at 1 site Interventional Ages 18 to 60

Cognitive behavioral therapy for insomnia in people with mild traumatic brain injury

Official title: Exploring Cognitive Behavioral Therapy for Insomnia (CBT-I) in Mild Traumatic Brain Injury (mTBI)

Run by University of Missouri-Columbia · NCT07385105 · Data updated 2026-11-12

This study will try cognitive behavioral therapy for insomnia (CBT-I) to see if it helps adults with mild traumatic brain injury sleep better and improve daily functioning.

Quick facts

Study typeInterventional
Ages18 Years to 60 Years
SexAll
Enrollment15 (estimated)
SponsorUniversity of Missouri-Columbia
Academic / other
Locations1 site (Columbia, Missouri)
StatusRecruiting
StartedMarch 1, 2026
Main results expectedApril 30, 2027
Study endsMay 30, 2027
Registry record updatedNovember 6, 2026
Trial IDNCT07385105 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with a physician-documented history of mild traumatic brain injury, English fluency, sleep problems lasting more than four weeks, and an ISI score of 10 or higher who do not have severe depression or anxiety and have a MoCA score of 24 or above.

Probably not a fit

People with other neurological or significant psychiatric conditions, severe depressive or anxiety symptoms (PHQ-9 >20 or GAD-7 >15), substantial cognitive impairment (MoCA <24), or without clinically significant insomnia (ISI <10) are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center interventional study will deliver a structured CBT-I program to adults with a documented history of mild traumatic brain injury who have had sleep problems for more than four weeks and an Insomnia Severity Index (ISI) score of 10 or higher. The intervention uses behavioral strategies and cognitive techniques to change sleep-disrupting habits and unhelpful beliefs about sleep. Key outcome measures include sleep metrics, mTBI symptom change, and functional performance in daily activities, with common exclusions for severe depression, severe anxiety, other neurologic/psychological disorders, or MoCA scores below 24. The trial is conducted at the University of Missouri–Columbia and collects pre- and post-intervention data to compare changes over time.

Why it matters

Potential benefit: If successful, CBT-I could improve sleep quality and help people with mTBI function better in their daily lives while reducing some mTBI-related symptoms.

How similar studies have gone: CBT-I is an evidence-based treatment that has produced strong results in many populations, but its effects specifically in individuals with mTBI have been studied only limitedly.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* A history of mTBI documented by a physician and sleep problems for more than 4 weeks
* A score ≥ 10 on the Insomnia Severity Index (ISI)
* Speak, read, and write English

Exclusion Criteria:

* History of other neurological or psychological conditions
* Patient Health Questionnaire-9 (PHQ-9) score higher than 20 (severe depressive symptoms)
* Generalized Anxiety Disorder-7 (GAD-7) score higher than 15 (severe anxiety symptoms)
* Montreal Cognitive Assessment (MoCA) score less than 24

Where it's running

  • University of Missouri-Columbia
    Columbia, Missouri, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.